KRRO Stock — Korro Bio Inc.: Cash, EV, Pipeline

Share price

$10.02

Market cap

$147.6M

Cash

$115.0M

Enterprise value

$32.6M

Balance sheet

Cash	$115.0M
Debt	$0.0M
Net cash	$115.0M
Enterprise value	$32.6M
Basic shares	14.7M shares
Fully diluted shares	17.1M shares
Fully diluted market cap	$171.5M
Cash per share	$7.82

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading KRRO daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Sep 12 - Oct 24	KRRO-121	Phase 2	Urea Cycle Disorders, Inborn; Urea Cycle Disorders; Ornithine Transcarbamylase (OTC) Deficiency	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

KRRO-110

Phase 1 · Terminated Modality: RNA editing

Target SERPINA1 transcript

Indications

alpha-1 antitrypsin deficiency (AATD) (Phase 1)

Status note Phase 1/2a REWRITE trial in AATD terminated in Q1 2026 after the trial did not produce positive results; KRRO-110 external R&D expenses fell ~$11.5M in H1 2026 on the termination.

KRRO-111

Preclinical · Active Modality: RNA editing (GalNAc-conjugated)

Target AAT (alpha-1 antitrypsin) protein repair

Indications

alpha-1 antitrypsin deficiency (AATD) (Preclinical)

Status note Development candidate for AATD announced May 2026; preclinical and manufacturing costs underway. Targets repair of the alpha-1 antitrypsin protein.

KRRO-121

Preclinical · Active Modality: RNA editing

Target ammonia clearance

Indications

urea cycle disorders / hyperammonemia (Preclinical)

Status note Hyperammonemia program targeting increased clearance of ammonia in multiple indications; preclinical and manufacturing costs underway.

AMPKγ1 program

Preclinical · Active Modality: RNA editing (GalNAc-conjugated)

Target AMPKγ1 pathway

Indications

liver health / longevity (Preclinical)

Status note Longevity and liver health program targeting activation of the AMPKγ1 pathway. No named candidate disclosed.

TDP-43 program

Preclinical · Active Modality: RNA editing (intrathecal delivery)

Target TDP-43

Indications

amyotrophic lateral sclerosis (ALS) (Preclinical)

Status note ALS program targeting creation of a de novo variant of TDP-43. No named candidate disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	KRRO-121
Lead indication	Urea Cycle Disorders, Inborn
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07773246	Phase 2	Not yet recruiting	Sponsor	KRRO	—	Urea Cycle Disorders, Inborn; Urea Cycle Disorders; Ornithine Transcarbamylase (OTC) Deficiency	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Korro Bio, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	540,054	no change	0.33%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

KRRO — Korro Bio Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders